Blog / Archives
Life Science Market Update: Risk Off, Raise Cash
Biotechnology Sector Outperforming Within NASDAQ A torrid run-up of over 10% in biotech stocks over the past 3 weeks brings caution to mind as the NASDAQ sell-off hits 1%. Over the past 5 days the...
Rayno Life Science Portfolio: Exelixis Up 10% Pre-Market On Takeover Talk
Exelixis (EXEL $12.17) has hired Goldman-Sachs to deal with potential takeover bids according to stories in Reuters and Bloomberg. Exelixis has a Phase III cancer drug XL184 (cabozantinab) and...
Rayno Life Science Portfolio: Biogen (BIIB) up 6.6 % on Positive MS Data
Biogen (BIIB $78.24) soared today on positive top line data on the Phase 3 Trial for oral BG-12 (dimethyl fumarate) as a montherapy in people with relapsing-remitting multiple sclerosis (RRMS)....
Rayno Life Science Portfolios:Illumina (ILMN) and Seattle Genetics(SGEN)
Reviewing Today's Action A mixed market today with a slight edge to the bulls. Immunogen(IMGN $12.28) up 4% continues its run from yesterday on positive data from its collboration with Roche on...
ThermoFisher (TMO) : Growth or Value?
Is there anybody who does not like ThermoFisher (TMO)stock? Thermofisher (TMO) has more fans than U2, Lady GaGa and Rihanna combined. Why is that? We are trying to find out.TMO is a life science...
Rayno Life Science Tools And Dx Portfolio Update:Immucor Beats 6/20 update
11/29/11 No new buys on tools/Dx since summer meltdown and Illumina (ILMN) miss. 6/20/11 NASDAQ (2632) Market stabilizing after 7% correction.QQQ down <1%. IBB up 10% YTD. Mid-cap biopharms are...
Needham Healthcare Conference Feeds Biotech Rally:Alexion (ALXN) and Seattle Genetics(SGEN)
Dr. Mark Monane Senior Analyst of Biotechnology at Needham & Co. was on CNBC today giving a turbo boost to the biotech rally that began in mid-March. 100 companies are presenting at the...
Rayno Biopharma Portfolio: Update 4/11,6/11, and 11/11,21/11
11/18 Added Dendreon (DNDN) at $8.00 level.IBB is preferred biotech ETF. 11/15/11 Comments: Under review: ImmunoGen (IMGN) Dropped FBT an ETF in favor of IBB or possibly XBI. For bullish equity...
Rayno Life Science Biopharmaceutical Portfolio:Cubist(CBST $28.40) Up 12% On Teva Licensing Deal
Cubist settles with TEVA on generic Cubicin. Cubist was added to the Rayno Life Science Portfolio on 2/2/09 at a price of $22. Teva gets right to generic daptomycin MRSA product on 6/24/18 and...
Rayno Life Science Tools and Dx: Exact Sciences (EXAS) and Qiagen(QGEN)
Platform Technologies Are In Demand: M&A Driver Intact Exact Sciences (EXAS $7.50) continued to run today up 3% and 1.3 pts in five days on no apparent news except presentations at recent...